Leukemia Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
4186 Etiology Of Alkylator-Induced Myeloid Leukemia
Select
16840A E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
09-130-B A University of Chicago Leukemia Registry Protocol.
10-064-B Molecular characterization of hematopoietic malignancies
Select
10-583-A AML08: A Phase III Randomized Trial of Clofarabine, Plus Cytarabine Versus Conventional Induction Therapy and a Phase III Study of Natural Killer Cell Transplantation in Patients With Newly Diangosed Acute Myeloid Leukemia
Select
10-617-A COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
11-0014 Evaluation of patients with hematopoietic malignancies and their family members for mutations in RUNX1, CEBPA, and p53.
Select
12-2179 A Phase 1/2, Open-label, Dose-escalation, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis
Select
12-1959 Initial Phase 1 Study of WT2725 Dosing Emulsion in Patients with Advanced Malignancies
IRB13-0716 Monitoring tyrosine kinase inhibitors (TKI) response in chronic myeloid leukemia (CML) patients by longitudinal collection and evaluation of 'omics' data
Select
12-2245 An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chlorambucil)
Select
IRB13-0858 A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (ERYASP) in Combination with the CALGB Regimen During Induction and Consolidation Phases for Frontline Therapy of Subjects Older than 40 Years with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Select
IRB14-0076 A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Select
IRB14-0059 A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Select
IRB14-0119 A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (Kpt-330) Versus Specified Physicians Choice in Patients More than 60 Years Old With Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Select
IRB14-0331 A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
Select
IRB14-0651 A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Na´ve Subjects with Acute Myelogenous Leukemia Who Are Older than 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Select
IRB14-1076 Phase I Study of an Oncofetal Antigen (OFA) Multi-Peptide Immunotherapy (BB-MPI-03) in Subjects with Hematologic Cancer
Select
IRB14-1538 The Life After Stopping Tyrosine Kinase Inhibitors Study
Select
IRB14-0702 A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)
Select
IRB14-0881 A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion
Select
12-1588 COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
Select
CIRB14-1184 COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Select
16070A A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Select
IRB15-0115 A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973)with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
Select
CIRB14-1100 E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Select
IRB14-1567 A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Select
IRB14-0381 E1912: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Select
IRB14-0085 A Phase II, Randomized Trial of Standard of Care, With or Without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
Select
CIRB14-1502 AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Select
10-586-A COG AALL08B1 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia
Select
IRB14-1299 Correlative Biomarkers Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD (MPD-RC 107) (Mandatory Companion Study to MPD-RC 104, 111,112, 114, and 109)
Select
CIRB15-0185 Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy
Select
IRB15-0132 A Phase 2, Open-Label Study Evaluating the Efficacy, Safety,Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies
Select
IRB14-1295 Combination Ruxolitinib and Decitabine in patients with Myeloproliferative Neoplasms in Accelerated and Blast Phase Disease (IND#119403)
Select
IRB14-1497 A Pivotal Multicenter Trial of Moxetumomab pasudotox in Relapsed/Refractory Hairy Cell Leukemia
Select
IRB15-0412 Phase I Study to Assess the Tolerability and Efficacy of Combining Selinexor with High Dose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy for Remission Induction in Acute Myelogenous Leukemia (AML)
Select
IRB15-0678 A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Select
IRB15-1167 A Phase III, Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
IRB15-1032 An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure during Induction Chemotherapy for Acute Myeloid Leukemia
IRB15-1161 A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team